Oragenics CMO to present ONP-002 at IPAC-RS; IND submission planned Q4 2026

ORAGENICS INC

CMO James P. Kelly presents ONP-002 intranasal neurosteroid for concussion at IPAC-RS 2026 Nasal Innovation Forum on Sept 17, 2026.
Phase IIa feasibility trial enrolling at 3 Australian sites; IND submission anticipated Q4 2026.
U.S. Phase IIb trials planned post-IND; no FDA-approved pharmacological treatment for mTBI exists.
Phase I safety trials completed with favorable safety/tolerability; ONP-002 targets neuroinflammation, oxidative stress, edema.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.